The consistencies in ER/PR/HER2 status between primary breast tumors and metastatic lymph nodes ranged from 75.9 to 100% (Amir et al. 2012; Lindström et al. 2012), which was likely ascribed to differential expression in primary and metastatic sites. This evidence concerns the gene ERBB2 and breast neoplasm.